openPR Logo
Press release

Hepatitis Drugs Market by Therapeutics, Diagnostics, Patient, Drugs Policy

06-12-2019 08:01 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: P&S Intelligence

Hepatitis Drugs Market by Therapeutics, Diagnostics, Patient,

The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.
Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market
Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest growth during the forecast period, with a CAGR of 30.7%.
The increasing incidences of various types of hepatitis, such as hepatitis B, and hepatitis C are playing a pivotal role in the growth of the global hepatitis drugs market. According to the Hepatitis B Foundation, a non-profit organization solely dedicated to the global problem of hepatitis B, approximately 400 million people globally were chronically infected with hepatitis B, as reported at the end of September 2015. According to the World Health Organization (WHO), an estimated 130 - 150 million people globally were reported to suffer from hepatitis C, as of July 2015. The increasing incidences of hepatitis have increased the demand of therapeutic drugs for the management of diseases.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market/report-sample
However, the high capital expenditure and stringent regulatory requirements are inhibiting the growth of the market. The growing number of collaboration and partnerships is one of the latest trends observed in the market.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hepatitis-drugs-market
Geographically, North America dominated the global market of hepatitis drugs in 2014; whereas the Asian market is expected to witness the fastest growth, with a CAGR of 32.4% during the forecast period.
The key companies operating in the global hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, and Mitsubishi Tanabe Pharma Corporation.

About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatitis Drugs Market by Therapeutics, Diagnostics, Patient, Drugs Policy here

News-ID: 1772258 • Views: 392

More Releases from P&S Intelligence

Australia E-Commerce in Automotive Aftermarket To Generate USD 3,822.2 Million b …
The Australia e-commerce in automotive aftermarket was worth around USD 1,503.5 million in 2022, and it will grow at a CAGR of 12.2% from 2022 to 2030, to touch USD 3,822.2 million by 2030, as per P&S Intelligence. This is due to the booming automotive aftermarket, escalating count of DIY customers, and convenience offered by online shopping platforms. Third-Party Retailers Account for Higher Product Sales The category of third-party retailers accounts for
North America Electric Scooters and Motorcycles Market Will Reach USD 2,348 Mill …
The North American electric scooters and motorcycles market was valued at USD 620 million in 2022, and this number is expected to reach USD 2,348 million by 2030, advancing at a CAGR of 18.10% during 2022-2030, according to P&S Intelligence. This development can be ascribed to supportive government initiatives, from both federal and state levels. To encourage the acceptance of electric vehicles, the government is offering tax rebates and subsidies
Exploring the Growth of the Hybrid Electric Car Market
Before we move to the various advantages of hybrid electric cars, let's first understand their mechanism. A hybrid vehicle comprises both the internal combustion engine and electric motor. The batteries provide power to the motor, facilitating the rotation of the wheels either on their own or by supplementing the engine while accelerating. To receive free sample pages of this report@ https://www.psmarketresearch.com/market-analysis/hybrid-electric-car-market/report-sample Why Is It Hybrid before Electric? Since hybrid electric cars are a
Autonomous Mobile Robots Market To Reach USD 10,979 Million by 2030
The total size of the autonomous mobile robots market was USD 3,148 million in 2022, and it will reach a value of USD 10,979 million by 2030, advancing at rate 16.90% in the years to come, as per a report by a market research company, P&S Intelligence. The logistics category had the largest share of revenue, of about 29% in the past. These robots are chiefly installed for transportation of goods

All 5 Releases


More Releases for Hepatitis

Is Hepatitis A Vaccine Required?
Hepatitis A Vaccine Market describes its growth, size, share, Forecast and trends to 2025 Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available
Hepatitis Drugs Market Is Growing Due to Increasing R&D Investments on Hepatitis …
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest
Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B In …
Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and
Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth
Global Hepatitis E Diagnostic Tests Market: Snapshot The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. There is increasing prevalence of hepatitis E in resource-limited region, such as various countries of Asia Pacific. The people of these regions suffer with frequent water contamination and have limited access to sanitation and hygiene,
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each